Development and Validation of a Clinical Decision Support Tool to Predict Disease Progression in Crohn's Disease Treated with Ustekinumab.

ABSTRACT: Background/Objectives: Ustekinumab (UST) is an effective and safe drug for treating Crohn's disease (CD), but data on disease progression after UST treatment is limited. This study aimed to develop a clinical decision support tool (CDST) to identify Chinese patients with CD less likely to experience disease progression during UST treatment. Methods: A multicenter, retrospective observational study was conducted among Chinese patients with CD who started UST treatment between 1 May 2020 and 20 October 2022. Baseline characteristics, defined as the measurements taken closest to, and prior to, the first dose of UST, were collected. Disease progression, defined as CD-related surgery, hospitalization, and complications, was evaluated by week 52 (±4 weeks). Predictors were identifi

SUBMITTER: Yao L 

PROVIDER: S-EPMC12653264 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature